Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical & Translational Metabolism
Published in: Clinical Reviews in Bone and Mineral Metabolism 2/2018

01-06-2018 | Review Paper

Testosterone and Male Osteoporosis

Authors: Dong-Eun Shin, Tae-Keun Ahn, Jee-Woong Kim, Chi-Hoon Oh, SeongJu Choi

Published in: Clinical & Translational Metabolism | Issue 2/2018

Login to get access

Abstract

Male osteoporosis is not a rare public health issue. The prevalence of hypogonadism increases with aging, and the gradual onset of moderate hypogonadism is the most common cause of male osteoporosis. Decreased testosterone levels with aging can directly or indirectly increase the risk of male osteoporosis and fractures. However, testosterone deficiency is not a universal feature of elderly men, and the association of testosterone with osteoporosis is not as strong as that of estrogen with osteoporosis in females; the effect of testosterone on male osteoporosis and treatment of osteoporosis is still controversial. Although many data and results have been released, the mechanism by which testosterone affects bone formation and resorption is not fully understood yet. Therefore, this review aims to present current knowledge about testosterone and male osteoporosis.
Literature
1.
Bouillon R, Burckhardt P, Christiansen C, Fleisch HA, Fujita T, Gennari C, et al. Consensus development conference: prophylaxis and treatment of osteoporosis. Am J Med. 1991;90:107–10.CrossRef
2.
Cooper C, Campion G, Melton L 3rd. Hip fractures in the elderly: a world-wide projection. Osteoporos Int. 1992;2(6):285–9.CrossRefPubMed
3.
Van Der Klift M, De Laet CE, Mccloskey EV, Hofman A, Pols HA. The incidence of vertebral fractures in men and women: the Rotterdam study. J Bone Miner Res. 2002;17(6):1051–6.CrossRefPubMed
4.
Melton LJ, Atkinson EJ, O’connor MK, O’fallon WM, Riggs BL. Bone density and fracture risk in men. J Bone Miner Res. 1998;13(12):1915–23.CrossRefPubMed
5.
6.
Kanis JA, Johnell O, Oden A, Sernbo I, Redlund-Johnell I, Dawson A, et al. Long-term risk of osteoporotic fracture in Malmö. Osteoporos Int. 2000;11(8):669–74.CrossRefPubMed
7.
Misiorowski W. Osteoporosis in men. Przeglad Menopauzalny Menopause Rev. 2017;16:70.CrossRef
8.
9.
10.
Vanderschueren D, Laurent MR, Claessens F, Gielen E, Lagerquist MK, Vandenput L, et al. Sex steroid actions in male bone. Endocr Rev. 2014;35(6):906–60.CrossRefPubMedPubMedCentral
11.
Mulligan T, Iranmanesh A, Veldhuis JD. Pulsatile iv infusion of recombinant human LH in leuprolide-suppressed men unmasks impoverished Leydig-cell secretory responsiveness to midphysiological LH drive in the aging male. J Clin Endocrinol Metab. 2001;86(11):5547–53.CrossRefPubMed
12.
Mulligan T, Iranmanesh A, Kerzner R, Demers LW, Veldhuis JD. Two-week pulsatile gonadotropin releasing hormone infusion unmasks dual (hypothalamic and Leydig cell) defects in the healthy aging male gonadotropic axis. Eur J Endocrinol. 1999;141(3):257–66.CrossRefPubMed
13.
Mahmoud AM, Goemaere S, El-Garem Y, Van Pottelbergh I, Comhaire FH, Kaufman JM. Testicular volume in relation to hormonal indices of gonadal function in community-dwelling elderly men. J Clin Endocrinol Metab. 2003;88(1):179–84.CrossRefPubMed
14.
Riggs BL, Khosla S, Melton LJ III. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev. 2002;23(3):279–302.CrossRefPubMed
15.
Mohr BA, Guay AT, O’donnell AB, McKinlay JB. Normal, bound and nonbound testosterone levels in normally ageing men: results from the Massachusetts male ageing study. Clin Endocrinol. 2005;62(1):64–73.CrossRef
16.
Muller M, den Tonkelaar I, Thijssen JH, Grobbee DE, van der Schouw YT. Endogenous sex hormones in men aged 40-80 years. Eur J Endocrinol. 2003;149(6):583–9.CrossRefPubMed
17.
Morley JE, Kaiser FE, Perry HM, Patrick P, Morley PM, Stauber PM, et al. Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism. 1997;46(4):410–3.CrossRefPubMed
18.
Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB, Coviello AD, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab. 2002;87(2):589–98.CrossRefPubMed
19.
Torjesen PA, Sandnes L. Serum testosterone in women as measured by an automated immunoassay and a RIA. Clin Chem. 2004;50(3):678–9.CrossRefPubMed
20.
Phillip M, Maor G, Assa S, Silbergeld A, Segev Y. Testosterone stimulates growth of tibial epiphyseal growth plate and insulin-like growth factor-1 receptor abundance in hypophysectomized and castrated rats. Endocrine. 2001;16(1):1–6.CrossRefPubMed
21.
Anderson FH, Francis RM, Selby PL, Cooper C. Sex hormones and osteoporosis in men. Calcif Tissue Int. 1998;62(3):185–8.CrossRefPubMed
22.
Finkelstein JS, Neer RM, Biller BM, Crawford JD, Klibanski A. Osteopenia in men with a history of delayed puberty. N Engl J Med. 1992;326(9):600–4.CrossRefPubMed
23.
Gennari L, Nuti R, Bilezikian JP. Aromatase activity and bone homeostasis in men. J Clin Endocrinol Metab. 2004;89(12):5898–907.CrossRefPubMed
24.
Carani C, Qin K, Simoni M, Faustini-Fustini M, Serpente S, Boyd J, et al. Effect of testosterone and estradiol in a man with aromatase deficiency. N Engl J Med. 1997;337(2):91–5.CrossRefPubMed
25.
Venken K, De Gendt K, Boonen S, Ophoff J, Bouillon R, Swinnen JV, et al. Relative impact of androgen and estrogen receptor activation in the effects of androgens on trabecular and cortical bone in growing male mice: a study in the androgen receptor knockout mouse model. J Bone Miner Res. 2006;21(4):576–85.CrossRefPubMed
26.
Hughes IA, Davies JD, Bunch TI, Pasterski V, Mastroyannopoulou K, MacDougall J. Androgen insensitivity syndrome. Lancet. 2012;380(9851):1419–28.CrossRefPubMed
27.
Mizuno Y, Hosoi T, Inoue S, Ikegami A, Kaneki M, Akedo Y, et al. Immunocytochemical identification of androgen receptor in mouse osteoclast-like multinucleated cells. Calcif Tissue Int. 1994;54(4):325–6.CrossRefPubMed
28.
Noble B, Routledge J, Stevens H, Hughes I, Jacobson W. Androgen receptors in bone-forming tissue. Horm Res Paediatr. 1999;51(1):31–6.CrossRef
29.
Colvard DS, Eriksen EF, Keeting PE, Wilson EM, Lubahn DB, French FS, et al. Identification of androgen receptors in normal human osteoblast-like cells. Proc Natl Acad Sci. 1989;86(3):854–7.CrossRefPubMedPubMedCentral
30.
Karsenty G. Transcriptional control of skeletogenesis. Annu Rev Genomics Hum Genet. 2008;9(1):183–96.CrossRefPubMed
31.
32.
Kasperk C, Helmboldt A, Börcsök I, Heuthe S, Cloos O, Niethard F, et al. Skeletal site-dependent expression of the androgen receptor in human osteoblastic cell populations. Calcif Tissue Int. 1997;61(6):464–73.CrossRefPubMed
33.
Nakano Y, Morimoto I, Ishida O, Fujihira T, Mizokami A, Tanimoto A, et al. The receptor, metabolism and effects of androgen in osteoblastic MC3T3-E1 cells. Bone Miner. 1994;26(3):245–59.CrossRefPubMed
34.
Damien E, Price JS, Lanyon LE. Mechanical strain stimulates osteoblast proliferation through the estrogen receptor in males as well as females. J Bone Miner Res. 2000;15(11):2169–77.CrossRefPubMed
35.
Huber DM, Bendixen AC, Pathrose P, Srivastava S, Dienger KM, Shevde NK, et al. Androgens suppress osteoclast formation induced by RANKL and macrophage-colony stimulating factor. Endocrinology. 2001;142(9):3800–8.CrossRefPubMed
36.
Hofbauer LC, Hicok KC, Chen D, Khosla S. Regulation of osteoprotegerin production by androgens and anti-androgens in human osteoblastic lineage cells. Eur J Endocrinol. 2002;147(2):269–73.CrossRefPubMed
37.
38.
Henriksen K, Neutzsky-Wulff AV, Bonewald LF, Karsdal MA. Local communication on and within bone controls bone remodeling. Bone. 2009;44(6):1026–33.CrossRefPubMed
39.
Wiren KM, Evans AC, Zhang XW. Osteoblast differentiation influences androgen and estrogen receptor-alpha and-beta expression. J Endocrinol. 2002;175(3):683–94.CrossRefPubMed
40.
Frenkel B, Hong A, Baniwal SK, Coetzee GA, Ohlsson C, Khalid O, et al. Regulation of adult bone turnover by sex steroids. J Cell Physiol. 2010;224(2):305–10.CrossRefPubMedPubMedCentral
41.
Hofbauer LC, Hicok KC, Khosla S. Effects of gonadal and adrenal androgens in a novel androgen-responsive human osteoblastic cell line. J Cell Biochem. 1998;71(1):96–108.CrossRefPubMed
42.
Kasperk CH, Wakley GK, Hierl T, Ziegler R. Gonadal and adrenal androgens are potent regulators of human bone cell metabolism in vitro. J Bone Miner Res. 1997;12(3):464–71.CrossRefPubMed
43.
Kasperk CH, Wergedal JE, Farley JR, Linkhart TA, Turner RT, Baylink DJ. Androgens directly stimulate proliferation of bone cells in vitro. Endocrinology. 1989;124(3):1576–8.CrossRefPubMed
44.
Szulc P, Claustrat B, Marchand F, Delmas PD. Increased risk of falls and increased bone resorption in elderly men with partial androgen deficiency: the MINOS study. J Clin Endocrinol Metab. 2003;88(11):5240–7.CrossRefPubMed
45.
Kuchuk NO, Van Schoor NM, Pluijm SM, Smit JH, De Ronde W, Lips P. The association of sex hormone levels with quantitative ultrasound, bone mineral density, bone turnover and osteoporotic fractures in older men and women. Clin Endocrinol. 2007;67(2):295–303.CrossRef
46.
Boonen S, Pye SR, O’Neill TW, Szulc P, Gielen E, Borghs H, et al. Influence of bone remodelling rate on quantitative ultrasound parameters at the calcaneus and DXA BMDa of the hip and spine in middle-aged and elderly European men: the European male ageing study (EMAS). Eur J Endocrinol. 2011;165(6):977–86.CrossRefPubMed
47.
Legrand E, Hedde C, Gallois Y, Degasne I, De Casson FB, Mathieu E, et al. Osteoporosis in men: a potential role for the sex hormone binding globulin. Bone. 2001;29(1):90–5.CrossRefPubMed
48.
Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J Clin Endocrinol Metab. 2001;86(2):724–31.CrossRefPubMed
49.
Mellström D, Johnell O, Ljunggren Ö, Eriksson A-L, Lorentzon M, Mallmin H, et al. Free testosterone is an independent predictor of BMD and prevalent fractures in elderly men: MrOS Sweden. J Bone Miner Res. 2006;21(4):529–35.CrossRefPubMed
50.
Meier C, Nguyen TV, Handelsman DJ, Schindler C, Kushnir MM, Rockwood AL, et al. Endogenous sex hormones and incident fracture risk in older men: the Dubbo osteoporosis epidemiology study. Arch Intern Med. 2008;168(1):47–54.CrossRefPubMed
51.
Kacker R, Conners W, Zade J, Morgentaler A. Bone mineral density and response to treatment in men younger than 50 years with testosterone deficiency and sexual dysfunction or infertility. J Urol. 2014;191(4):1072–6.CrossRefPubMed
52.
Nguyen HT, von Schoultz B, Nguyen TV, Thang TX, Chau TT, Duc PT, et al. Sex hormone levels as determinants of bone mineral density and osteoporosis in Vietnamese women and men. J Bone Miner Metab. 2015;33(6):658–65.CrossRefPubMed
53.
Snyder PJ, Kopperdahl DL, Stephens-Shields AJ, Ellenberg SS, Cauley JA, Ensrud KE, et al. Effect of testosterone treatment on volumetric bone density and strength in older men with low testosterone: a controlled clinical trial. JAMA Intern Med. 2017;177(4):471–9.CrossRefPubMedPubMedCentral
54.
Vandenput L, Mellström D, Laughlin GA, Cawthon PM, Cauley JA, Hoffman AR, et al. Low testosterone, but not estradiol, is associated with incident falls in older men: the international MrOS study. J Bone Miner Res. 2017;32(6):1174–81.CrossRefPubMed
55.
Smith MR, Boyce SP, Moyneur E, Duh MS, Raut MK, Brandman J. Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol. 2006;175:136–139.
56.
Wang A, Obertová Z, Brown C, Karunasinghe N, Bishop K, Ferguson L, et al. Risk of fracture in men with prostate cancer on androgen deprivation therapy: a population-based cohort study in New Zealand. BMC Cancer. 2015;15(1):837.CrossRefPubMedPubMedCentral
57.
Hsu B, Seibel MJ, Cumming RG, Blyth FM, Naganathan V, Bleicher K, et al. Progressive temporal change in serum SHBG, but not in serum testosterone or estradiol, is associated with bone loss and incident fractures in older men: the concord health and ageing in men project. J Bone Miner Res. 2016;31(12):2115–22.CrossRefPubMed
58.
LeBlanc ES, Nielson CM, Marshall LM, Lapidus JA, Barrett-Connor E, Ensrud KE, et al. The effects of serum testosterone, estradiol, and sex hormone binding globulin levels on fracture risk in older men. J Clin Endocrinol Metab. 2009;94(9):3337–46.CrossRefPubMedPubMedCentral
59.
Khosla S, Melton LJ, Riggs BL. The unitary model for estrogen deficiency and the pathogenesis of osteoporosis: is a revision needed? J Bone Miner Res. 2011;26(3):441–51.CrossRefPubMed
60.
Cawthon PM, Shahnazari M, Orwoll ES, Lane NE. Osteoporosis in men: findings from the osteoporotic fractures in men study (MrOS). Ther Adv Musculoskelet Dis. 2016;8(1):15–27.CrossRefPubMedPubMedCentral
61.
Zha X-Y, Hu Y, Pang X-N, Zhu J-H, Chang G-L, Li L. Sex hormone-binding globulin (SHBG) as an independent determinant of bone mineral density (BMD) among Chinese middle-aged and elderly men. Endocrine. 2014;47(2):590–7.CrossRefPubMed
62.
Vandenput L, Mellström D, Kindmark A, Johansson H, Lorentzon M, Leung J, et al. High serum SHBG predicts incident vertebral fractures in elderly men. J Bone Miner Res. 2016;31(3):683–9.CrossRefPubMedPubMedCentral
63.
Mellström D, Vandenput L, Mallmin H, Holmberg AH, Lorentzon M, Odén A, et al. Older men with low serum estradiol and high serum SHBG have an increased risk of fractures. J Bone Miner Res. 2008;23(10):1552–60.CrossRefPubMed
64.
Watts NB, Adler RA, Bilezikian JP, Drake MT, Eastell R, Orwoll ES, et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97(6):1802–22.CrossRefPubMed
65.
66.
67.
68.
Bouloux PM, Legros J-J, Elbers JM, Geurts TP, Kaspers MJ, Meehan AG, et al. Effects of oral testosterone undecanoate therapy on bone mineral density and body composition in 322 aging men with symptomatic testosterone deficiency: a 1-year, randomized, placebo-controlled, dose-ranging study. Aging Male. 2013;16(2):38–47.CrossRefPubMed
69.
Rodriguez-Tolrà J, Torremadé J, Di Gregorio S, Del Rio L, Franco E. Effects of testosterone treatment on bone mineral density in men with testosterone deficiency syndrome. Andrology. 2013;1(4):570–5.CrossRefPubMed
70.
Boonen S, Reginster J-Y, Kaufman J-M, Lippuner K, Zanchetta J, Langdahl B, et al. Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med. 2012;367(18):1714–23.CrossRefPubMed
71.
Lang JM, Wallace M, Becker JT, Eickhoff JC, Buehring B, Binkley N, et al. A randomized phase II trial evaluating different schedules of zoledronic acid on bone mineral density in patients with prostate cancer beginning androgen deprivation therapy. Clin Genitourin Cancer. 2013;11(4):407–15.CrossRefPubMed
72.
Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 2003;169(6):2008–12.CrossRefPubMed
73.
Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000;343(9):604–10.CrossRefPubMed
74.
Nakamura T, Matsumoto T, Sugimoto T, Hosoi T, Miki T, Gorai I, et al. Clinical trials express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT). J Clin Endocrinol Metab. 2014;99(7):2599–607.CrossRefPubMedPubMedCentral
75.
Langdahl BL, Teglbj A erg CS, ho P-R, Chapurlat R, Czerwinski E, Kendler DL, et al. A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial. J Clin Endocrinol Metab 2015;100(4):1335–1342.
76.
Smith MR, Egerdie B, Toriz NH, Feldman R, Tammela TL, Saad F, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361(8):745–55.CrossRefPubMedPubMedCentral
77.
Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, et al. The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosis. J Bone Miner Res. 2003;18(1):9–17.CrossRefPubMed
78.
Niimi R, Kono T, Nishihara A, Hasegawa M, Matsumine A, Sudo A. Analysis of daily teriparatide treatment for osteoporosis in men. Osteoporos Int. 2015;26(4):1303–9.CrossRefPubMed
79.
Kaufman J-M, Orwoll E, Goemaere S, San Martin J, Hossain A, Dalsky GP, et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int. 2005;16(5):510–6.CrossRefPubMed
Metadata
Title
Testosterone and Male Osteoporosis
Authors
Dong-Eun Shin
Tae-Keun Ahn
Jee-Woong Kim
Chi-Hoon Oh
SeongJu Choi
Publication date
01-06-2018
Publisher
Springer US
Published in
Clinical & Translational Metabolism / Issue 2/2018
Print ISSN: 1534-8644
Electronic ISSN: 2948-2445
DOI
https://doi.org/10.1007/s12018-018-9245-0
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits